Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Stereotactic Radiotherapy, Immunotherapy...
Phase PHASE2
Enrollment 136
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study was an open-label, multicenter, randomized study. It is planned to include 136 patients with stage II-III triple negative breast cancer. Eligible subjects will be randomized to receive either the experimental arm: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) or the control arm: adebrelimab plus nab-paclitaxel + carboplatin.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) — Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
  • Drug: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) — adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)

Primary Outcomes

  • tpCR (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-09-26
Completion: 2028-12-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 136 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shengjing Hospital
Contact Information
Study Contact:
Caigang Liu, Dr.
18940254967
liucg@sj-hospital.org
Nan Niu, Dr.
18940256668
niunannancy@163.com
Nan Niu, Phd
+8618940256668
niun@sj-hospital.org
Shengjing Hospital of China Medical University
Interventions
  • Drug: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) — Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
  • Drug: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) — adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
Study Locations (1 sites)
Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022 China
Eligibility Criteria
Inclusion Criteria: * Treatment-naïve breast cancer female patients aged ≥ 18 years and ≤ 75 years; * Histopathologically confirmed early or locally advanced triple-negative invasive breast cancer according to the latest ASCO/CAP guidelines, meeting the following conditions: (1) pathological type is triple-negative, specifically: ER negative: IHC \< 1%, PR negative: IHC \< 1%, HER2 negative: IHC 0/1 + or IHC2 + but ISH negative; * Clinical stage II-III invasive breast cancer with measurable lesions according to RECIST 1.1; * ECOG score 0-1; * Able to tolerate preoperative and postoperative adjuvant radiotherapy after assessment by a radiologist; * Appropriate level of organ function * Patients voluntarily participate in and sign the informed consent form, are expected to have good compliance and cooperate with the study according to the requirements of the protocol. Exclusion Criteria: * Patients with metastatic breast cancer or bilateral breast cancer; * Patients with inflammatory breast cancer or occult breast cancer; * Patients received any anti-tumor therapy within 12 months before signing the informed consent form, including chemotherapy, targeted therapy, radiotherapy, endocrine therapy, immunotherapy, biological therapy or tumor embolization; * Patients previously received PD-1/PD-L1 antibody, CTLA-4 antibody, or other treatments against PD-1/PD-L1 inhibitors; * Female patients who are pregnant and lactating, female patients who are fertile and have a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial. * Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia, and the subject has a known history of psychotropic drug abuse, alcoholism ; * Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); positive hepatitis B surface antigen (HBsAg) test, or positive hepatitis B core antibody (HBcAb) test followed by positive HBV-DNA test (HBV-DNA test was performed only in patients with negative HBsAg test and positive HBcAb test); positive hepatitis C virus (HCV) antibody test followed by positive HCV-RNA test (HCV-RNA test was performed only in patients with positive HCV antibody test) * Any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.
Conditions Benzodiazepine Adverse Reaction, Depress...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study explores the impact of long-term benzodiazepine (BZDs) use on cognitive function and associated neuroimaging markers. While BZDs are established treatments for conditions like anxiety and insomnia, recent warnings highlight risks, including neurocognitive effects. Neuroimaging studies indicate potential neuroprotective effects of BZDs. Functional near-infrared spectroscopy (fNIRS) measures cerebral cortex function during cognitive tasks. Combining fNIRS with mood and cognitive scales, this study assesses cortical activation. 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) evaluates brain metabolism. DPA-714 PET assesses neuroinflammation. The primary objective is to compare brain functional activation, metabolism, and neuroinflammatory levels between long-term BZD users and non-users. This comprehensive approach aims to provide insights into BZD effects on cognition and associated brain markers.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Brain hemodynamic activity with fNIRS (for 3 years)
  • Longitudinal evolution of biomarkers measured from neuroimaging (including structural, functional, and multimodal MRI) and molecular neuroimaging (18F-FDG PET/MRI、DPA-714-PET/MRI) (for 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-11
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Dalian Medical University
Principal Investigators:
  • Hui min Zhang (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital of Dalian Medical University
Contact Information
Study Contact:
Hui min Zhang
+86 18098876233
huiminzhangxs@163.com
Mei chen Liu
+86 18098871637
meichenliu9019@163.com
Hui min Zhang
+86 18098876233
huiminzhangxs@163.com
The First Affiliated Hospital of Dalian Medical University
Interventions
N/A
Study Locations (1 sites)
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000 China
Eligibility Criteria
Inclusion Criteria: 1. Continuous use of benzodiazepines for ≥3 months, matched with participants who have not taken benzodiazepines. 2. Education time ≥6 years. 3. Abstained from alcohol, coffee, and other psychoactive substances in the 24 hours before the examination. Exclusion Criteria: 1. Brain damage due to various reasons (such as head trauma, dementia, epilepsy, brain tumors, etc.). 2. Severe systemic diseases (such as malignant tumors, etc.). 3. Acute cerebrovascular disease in the past 3 months. History of substance abuse other than benzodiazepines (such as alcohol, opioids, etc.). 4. Inability to cooperate with fNIRS, PET/MRI examinations, and scale assessments.
Conditions Post Traumatic Stress Disorder (PTSD), D...
Phase NA
Enrollment 300
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The VA wants to understand what type of integrative and whole health approaches are helpful for Veterans. The study is comparing two primary care based mental health treatments, a mindfulness class that teaches mindfulness meditation and a problem-solving class that teaches problem-solving skills and how to build resilience, for Veterans who are experiencing symptoms of anxiety, depression, and/or PTSD. The goal of the study is to understand if the classes reduce symptoms of anxiety, depression, and/or PTSD and increase overall functioning.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Primary Care Brief Mindfulness Training (PCBMT) — PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
  • Behavioral: Moving Forward (MF) — Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as "stop, slow down, think and act". The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion.

Primary Outcomes

  • Depression Anxiety and Stress Scale (DASS-21) Change (Up to 24 weeks: Baseline, 8 weeks, 16 weeks, 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-19
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Kyle Possemato, PhD (PRINCIPAL_INVESTIGATOR) - Syracuse VA Medical Center, Syracuse, NY
Contact Information
Study Contact:
Kyle Possemato, PhD
(315) 425-4400
kyle.possemato@va.gov
Ariella Davis
Ariella.Davis@va.gov
Jenna L Gress-Smith
(480) 397-2927
Jenna.Gress-Smith@va.gov
Phoenix VA Health Care System, Phoenix, AZ
Interventions
  • Behavioral: Primary Care Brief Mindfulness Training (PCBMT) — PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
  • Behavioral: Moving Forward (MF) — Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as "stop, slow down, think and act". The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion.
Study Locations (4 sites)
Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona 85012 United States
VA San Diego Healthcare System, San Diego, CA, San Diego, California 92161-0002 United States
St. Louis VA Medical Center John Cochran Division, St. Louis, MO, St Louis, Missouri 63106-1621 United States
Syracuse VA Medical Center, Syracuse, NY, Syracuse, New York 13210-2716 United States
Eligibility Criteria
Inclusion Criteria: To be eligible, participants must be: * enrolled in VA primary care through the local VA site * report clinically significant psychological distress as measured in at least one of three areas: * PTSD operationalized by 30 on the PCL-5 plus endorsing a criteria A stressor * depression operationalized as 10 on the PHQ-9 * anxiety operationalized by 10 on the GAD-7 Exclusion Criteria: Exclusion criteria are minimized to allow inclusion of any primary care patients with psychological distress that would normally receive treatment in primary care. Patients will be excluded if they demonstrate symptoms that would not allow them to actively participate in the interventions: * gross cognitive impairment * suicide attempt or desire to commit suicide in the last month To allow the study to isolate the effects of the intervention and ensure patient treatment preferences are honored, patients will be excluded if they: * had a psychotherapy appointment outside of primary care within the last month and have future appointment scheduled * had a change in psychiatric medication outside of VHA primary care in the last 2 months * voice a preference to be directly referred to specialty mental health care Veterans with mild TBI, and alcohol/ substance use disorders will not be excluded because these problems commonly co-occur with psychological distress, and individuals with these conditions have previously benefited from mindfulness and problem-solving training. Patients who receive Primary Care Mental Health Integration (PCMHI) services will not be excluded as this is part of the usual primary care services that all Veterans receive.
Conditions Depression, Anxiety, Psilocybin-Assisted...
Phase PHASE2
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Psilocybin — Given by PO
  • Other: Niacin — Given by PO

Primary Outcomes

  • Safety and adverse events (AEs) (Through study completion; an average of 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-16
Completion: 2026-12-31
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: Gateway for Cancer Research
Principal Investigators:
  • Moran Amit, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Moran Amit, MD
(713) 794-5304
mamit@mdanderson.org
Moran Amit, MD
713-794-5304
mamit@mdanderson.org
MD Anderson Cancer Center
Moran Amit, MD
MD Anderson Cancer Center
Interventions
  • Drug: Psilocybin — Given by PO
  • Other: Niacin — Given by PO
Study Locations (1 sites)
MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Participants must have one of the following histology documented tumor types: non-small cell lung carcinoma, renal cell carcinoma, urothelial carcinoma, prostate cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer, gastric/GEJ cancer, cervical, anal, or MSI-high 2. Documentation of locally advanced, recurrent, or metastatic incurable malignancy that has partially responded or progressed after at least 1 available standard therapy and disease is stable (no progression of disease for 3 months or more on current treatment regimen) 3. No prior grade 3 AEs on current standard of care cancer treatment regimen; 4. Age ≥ 25 years; as by the age of 25 brain is fully developed. 5. Have a DSM-V psychiatric diagnosis, as determined by the SCID (Structured Clinical Interview for DSM, by a board certified psychiatrist), of one or more of the following Axis I psychiatric disorders that is judged to have been precipitated by the psychological stress of the cancer diagnosis: Generalized Anxiety Disorder; Acute Stress Disorder; Posttraumatic Stress Disorder; Major Depressive Disorder; Dysthymic Disorder; Adjustment Disorder with Anxiety; Adjustment Disorder with Depressed Mood; Adjustment Disorder with Mixed Anxiety and Depressed Mood; Adjustment Disorder with Disturbance of Conduct; Adjustment Disorder with Disturbance of Emotions and Conduct. Psychiatric diagnosis are determined by a MD Anderson board certified psychiatrist. 6. At least 6 months life expectancy as per primary medical oncologist. 7. Have an ECOG performance status of 0, 1, or 2. 8. Must have no major cognitive impairment and be oriented to person, place, and time (e.g. mini mental exam). 9. Must demonstrate willingness to travel to MD Anderson Cancer center for all treatment and follow-up sessions, as well as consent to complete all evaluation instruments and assessments. 10. Agree to abstain from any nicotine products for at least 12 hours prior to psilocybin administration until approximately 12 hours after (or when all post-session questionnaires have been completed) as well as on days of salivary sample collection. 11. Refrain from any psychoactive drugs (including alcohol) for 48 hours prior to psilocybin sessions (except as described above for nicotine and caffeine) and must refrain from psychoactive drugs 12 hours after psilocybin sessions. Must consent to urine drug screen (UDS) which will be given before receiving psilocybin. Participants with positive drug test will be retested (UDS) after 6 weeks and included if the repeated UDS is negative. Participant tested positive for a prescribed substance are eligible. Participant failing on the 2nd test (UDS) will be excluded. 12. Must be free from any regularly scheduled psychotropic (antidepressant/anxiolytic class) medications and those with primary MOA on serotonergic neurons (e.g., ondansetron) for a minimum of 2 weeks prior to study or 4 weeks for SSRI. Intermittent or PRN use of short-acting anxiolytics may be permitted as defined below in exclusionary criteria). 13. Inhibitors of monoamine oxidase, UGT1A9, 1A10, and aldehyde or alcohol dehydrogenase should be discontinued 5 half-lives prior to active dose of psilocybin. 14. Eligible participants will have a responsible individual that will provide transportation home after the psilocybin session is complete. 15. Fluent in English Exclusion Criteria: 1. History of depression prior to cancer diagnosis. 2. Clinically significant suicidality or high risk of completed suicide defined as: i. Answer 'Yes' to C-SSRS Suicidal Ideation items 4 or 5 within the last 2 months at Screening or 'since last visit' at Baseline ii. Report having had any C-SSRS Suicidal Behavior item within the past 12 months at Screening or 'since last visit' at Baseline, as defined by 'Yes' to any of the following on the C-SSRS: actual attempt, interrupted attempt, aborted attempt, or preparatory acts iii. Have any suicidal ideation or thoughts, in the opinion of the study physician or PI, that presents a serious risk of suicidal or self-injurious behavior 3. History of bipolar disorder, psychosis (of any nature), and seizures. 4. Functionally limiting comorbid conditions such as second primary malignancies in CNS or chest, and history of total laryngectomy or total .glossectomy. 5. ECG with QTc \> 450. 6. Patients with metal implants. 7. Asymptomatic ALT or AST elevations \>/= 5X upper limit of normal, symptomatic ALT or AST elevations \>/= 2X upper limit of normal, or total bilirubin \>/= 2X upper limit of normal. 8. The effects of psilocybin on the developing human fetus are unknown. For this reason, pregnant women will be excluded (Urine test for screening), women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following: Postmenopausal (no menses in greater than or equal to 12 consecutive months). History of hysterectomy or bilateral salpingo-oophorectomy. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). History of bilateral tubal ligation or another surgical sterilization procedure. Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 9. persons with first- or second-degree relatives who have schizophrenia or other psychotic disorders, or bipolar I or II disorder. 10. Actively progressing disease as defined by the primary oncologist. 11. Vulnerable populations, including children and cognitively impaired patients, will not be enrolled in this study. 12. Participants with brain metastases. 13. Risk for hypertensive crisis defined as Screening, Baseline, and Medication Session (prior to dosing) Blood Pressure \>140/90 mmHg and HR\> 90 bpm. 14. Unstable medical conditions or serious abnormalities of complete blood count, chemistries, or ECG that in the opinion of the study physician would preclude safe participation in the trial. Some examples include: i. Uncompensated congestive heart failure ii. Clinically significant arrhythmias (e.g., ventricular fibrillation, torsades) or clinically significant ECG abnormality (i.e., QTC interval \> 450) iii. Recent acute myocardial infarction or evidence of ischemia iv. Malignant hypertension v. Congenital long QT syndrome vi. Acute renal failure vii. Severe hepatic impairment viii. Respiratory failure 15. Significant central nervous system (CNS) pathology. Some examples include: i. Primary or secondary cerebral neoplasm ii. Epilepsy iii. History of stroke iv. Cerebral aneurysm v. Dementia vi. Delirium 16. a. High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation. Examples include: i. Agitation ii. Violent behavior b. Active substance use disorders (SUDs) defined as: DSM-5 criteria for moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine) within the past year c. Extensive use of serotonergic hallucinogens (e.g., LSD, psilocybin) defined as: i.
Conditions Asthma in Children
Phase NA
Enrollment 570
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Nav-Team study reviews how well the asthma navigators/coordinator program can improve the lives of asthmatic children, and their caregivers, by providing additional assistance and education. Aim 1 of the study will partner with immigrant serving community organizations to hold meetings that will help tailor the programs. Aim 2 of the study looks at data to help see if the program is working to help children and their caregivers. Aim 2a looks at difference in emergency department use between families that did not use the Nav-Team program and those that did. Aim 2b reviews how well the Nav-Team program did with reaching and connecting with the asthma child and caregiver community. Aim 2b, also reviews the costs of the program, how well the program did will sticking to the program goals, and how well the staff was able to keep up with providing education and help.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Double

Interventions / Regimen

  • Other: Experimental: Nav-Team — Participants in this arm will receive additional assistance related to asthma, log encounters, complete surveys.

Primary Outcomes

  • Asthma-related emergency department (ED) utlization (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-21
Completion: 2028-10
Eligibility
Age: 4 Years and older
Sex: ALL
Volunteers: false
Enrollment: 570 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Contact Information
Study Contact:
Lisa Ross DeCamp, MD, MPH
3037246499
lisa.decamp@cuanschutz.edu
Rose Prieto
303.724.9785
rosa.prieto@cuanschutz.edu
Lisa DeCamp, MD
303-724-6499
lisa.decamp@cuanchutz.edu
Children's Hospital Colorado
Interventions
  • Other: Experimental: Nav-Team — Participants in this arm will receive additional assistance related to asthma, log encounters, complete surveys.
Study Locations (1 sites)
Children's Hospital Colorado, Aurora, Colorado 80045 United States
Eligibility Criteria
eria for Nav-TEAM Intervention Dyads include: * Child aged 4-12 years. * Child with persistent asthma (defined by currently prescribed controller medication). * Parent/legal guardian who is at least 18 years old. Exclusion criteria for Nav-TEAM Intervention Dyads include: * Child aged under 4 and over 12 years of age. * Child with no persistent asthma (defined by currently prescribed controller medication). * Parent/legal guardian who is under 18 years old. * Any parent/legal guardian whose preferred spoken language is English. * Child requires additional continuous respiratory support (e.g,. tracheostomy with home ventilation, continuous daytime oxygen). * Child is enrolled in another study health system associated asthma navigation program (e.g. school or home-visiting programs). * Spoken non-English preferred healthcare language of parent/legal guardian. * Child does NOT require additional continuous respiratory support (e.g., nighttime use of Continuous positive airway pressure machine for obstructive sleep apnea would be eligible). * Child does NOT have a complex medical/genetic condition that affects swallowing or lung function (e.g. g-tube with aspiration, cystic fibrosis) * Child is NOT enrolled in another study health system associated asthma navigation program (e.g. school or home-visiting programs).

Protocol CAUSE-03 / CHEETAH

NCT06136091
Recruiting
Conditions Asthma
Phase Not Applicable
Enrollment 310
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot have used asthma medications in the year prior to enrollment and cannot demonstrate bronchodilator reversibility at baseline. Phenotypic characteristics will be established at baseline, and the participants will be seen at scheduled visits over 12 months. Each participant will be asked to monitor and self-report cold symptoms and will be asked to complete up to three cold visits

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Asthma disease activity measured by the number of exacerbations during the 12-month observation period (Month 0 to Month 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-08
Completion: 2027-09-01
Eligibility
Age: 6 Years and older
Sex: ALL
Volunteers: true
Enrollment: 310 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigators:
  • Andrew Liu, M.D. (STUDY_CHAIR) - Children's Hospital Colorado: Allergy Program
  • Matthew C. Altman, M.D., M.Phil. (STUDY_CHAIR) - Benaroya Research Institute at Virginia Mason: Systems Immunology Division
Contact Information
Study Contact:
Juana Cerna-Sanchez
720-777-8384
juana.cerna@childrenscolorado.org
Children's Hospital Colorado: Allergy Program
Cassandra Pelkey
202-476-2606
cpelkey@childrensnational.org
Children's National Medical Center: Children's Research Institute
Sarah Godley
312-227-6454
sgodley@luriechildrens.org
Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology
Interventions
N/A
Study Locations (8 sites)
Children's Hospital Colorado: Allergy Program, Aurora, Colorado 80045 United States
Children's National Medical Center: Children's Research Institute, Washington D.C., District of Columbia 20010 United States
Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology, Chicago, Illinois 60611 United States
Boston University School of Medicine: Pulmonary Center, Boston, Massachusetts 02118 United States
Boston Children's Hospital: Department of Immunology, Boston, Massachusetts 02215 United States
Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute, New York, New York 10029 United States
Columbia University Medical Center: Division of Pediatric Pulmonology, New York, New York 10032 United States
Cincinnati Children's Hospital Medical Center: Asthma Center, Cincinnati, Ohio 45229 United States
Eligibility Criteria
Inclusion Criteria: 1. Participant and/or parent guardian must be able to understand and provide informed consent and assent 2. Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-03 Manual of Operations (MOP) a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion 3. Either: 1. Have had a diagnosis of asthma made \> 1 year prior to recruitment; participants who received an asthma diagnosis by a clinician \<= 1 year prior to recruitment must report that their respiratory symptoms were present for more than 1 year prior to recruitment (asthma group), or 2. No report of ever being diagnosed with asthma (non-asthma group) 4. Either: 1. Require at least Step 2 therapy at the Screening/Enrollment Visit (asthma group), or 2. Have not used any asthma medications in the prior year (non-asthma group) 5. Are able to perform acceptable and repeatable spirometry per American Thoracic Society (ATS) criteria prior to enrollment 6. Have documentation of current medical insurance with prescription coverage at the Screening/Enrollment Visit 7. Participant and/or parent guardian has a smartphone compatible with the study electronic Patient Reported Outcomes (ePRO) system, Medidata Patient Cloud, and is willing to download one application for study use Exclusion Criteria: 1. Parent or guardian is not able or willing to give written informed consent or comply with study protocol 2. Have concurrent medical problems that would require systemic corticosteroids or other immunomodulators during the study 3. Are currently receiving immunotherapy 4. Are currently receiving treatment with a biologic therapy or have received a biologic therapy within 3 months prior to enrollment 5. Are currently requiring greater than fluticasone 500 mcg bid plus Long-Acting Beta Agonists (LABA) one puff twice daily or its equivalent plus Long Acting Muscarinic Antagonists (LAMA) and/or individuals using oral corticosteroids daily or every other day for more than 14 days at the time of the Screening/Enrollment Visit 6. Are currently pregnant or lactating, or plan to become pregnant during the time of study participation. Females of child-bearing potential (post-menarche) must be abstinent or use a medically acceptable birth control method throughout the study (i.e., oral subcutaneous, mechanical, or surgical contraception) 7. Have a known, pre-existing clinically important lung condition other than asthma. 8. Have a current malignancy or previous history of cancer in remission for less than 12 months prior to enrollment 9. Have a known immunodeficiency disease 10. Use of investigational drugs within 4 weeks of enrollment 11. Have past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study 12. If in the asthma group, will not allow the study clinician, an asthma specialist, to manage their disease for the duration of the study or who are not willing to change their asthma medications to follow Protocol CAUSE-03 CHEETAH 13. If in the non-asthma group, having bronchodilator reversibility (improvement in Forced expiratory volume in 1 second (FEV1) with albuterol \> = 10%) at the Screening/Enrollment visit 14. Have had a life-threatening asthma exacerbation in the last 2 years requiring intubation, mechanical ventilation or resulting in a hypoxic seizure. Potential participants may be reassessed as outlined in the Protocol CAUSE-03 Manual of Procedures (MOP)
Conditions Diabetes Mellitus Type 2
Phase NA
Enrollment 525
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

There is an urgent need for better control and prevention of complications in type 2 diabetes mellitus (T2DM). Behavioural change is critical, and while literature suggests that motivational interviewing (MI) may be effective in improving glycemic control, none has explored app-based MI designed specifically for T2DM. The overall objective of this project is to determine the effectiveness of primary care model combining app-based MI and AI-powered personalised nudges delivered through a mobile application (app) for diabetes management (EMPOWER-PLUS). The project aims to evaluate the effectiveness and implementation of MI and nudges through EMPOWERPLUS to deliver diabetes management through a randomised controlled trial (RCT). This will be a 3-arm RCT with primary outcome measure being the difference in HbA1c level at week 36 between the intervention and control arms. Secondary outcome measures include cost-effectiveness, quality of life, medication adherence, diet, and physical activity. Eligible poorly controlled T2DM patients with T2DM in polyclinics will be randomized to intervention arm who will receive EMPOWER-PLUS and smartwatch wearable on top of their usual clinical care. The first control group will have access to nudges delivered through app and smartwatch wearable in addition to usual clinical care but will not receive MI. The second control group will receive usual care (no access to MI, nudges and smartwatch wearable). This study is important to improve T2DM outcomes and reduce healthcare utilization by providing scientifically evaluated and transformative primary care model. Leveraging on digital technology and artificial intelligence to drive personalised care, behavioural change and empowerment has huge potential for scale up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: App-based Motivational Interviewing & Human health coaching — Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking. App-based Motivational Interviewing \& Human health coaching: The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call.
  • Behavioral: Empower+ App & Smartwatch wearable tracker — Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.

Primary Outcomes

  • HbA1c (9 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-23
Completion: 2026-06-30
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 525 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Singapore General Hospital
Collaborators: SingHealth Polyclinic - Sengkang, SingHealth Polyclinic - Punggol, SingHealth Polyclinic - Tampines, Tiong Bahru Community Health Centre
Principal Investigators:
  • Lian Leng Low (PRINCIPAL_INVESTIGATOR) - Singhealth Foundation
Contact Information
Study Contact:
Lian Leng Low
63265872
low.lian.leng@singhealth.com.sg
Yan Ling Quah
quah.yan.ling@singhealth.com.sg
SingHealth Polyclinic (Punggol)
Wei Mei Jeremy Koh
jeremy.koh.w.m@singhealth.com.sg
SingHealth Polyclinic (Sengkang)
Interventions
  • Behavioral: App-based Motivational Interviewing & Human health coaching — Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking. App-based Motivational Interviewing \& Human health coaching: The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call.
  • Behavioral: Empower+ App & Smartwatch wearable tracker — Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.
Study Locations (3 sites)
SingHealth Polyclinic (Punggol), Singapore, Singapore
SingHealth Polyclinic (Sengkang), Singapore, Singapore
SingHealth Polyclinic (Tampines), Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: * Aged 21 years and above * Have been diagnosed with diabetes (T2DM) * Had HbA1c result of ≥ 7.5% within past 3 months * Physically able to exercise * Able to read and converse in English * Able to download the Empower+ app, use the smartphone wearable tracker, and conform to the minimum smartwatch and app monitoring schedule Exclusion Criteria: * On bolus insulin treatment * Require assistance with basic activities of daily living (BADL) * Have planned major operation or surgical procedure within 9 months from the time of recruitment * Cognitively impaired (scored \&lt; 6 on the Abbreviated Mental Test) * Currently pregnant or lactating * Current participants of ongoing clinical trials involving the usage of a smartphone wearable tracker or mobile health app to assist diabetes management * Past Empower study participants who refused to participate in future Empower studies
Conditions Major Depressive Disorder
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life for individuals with depression is unclear. The investigators will assess how the participants' quality of life and psychomotor profile change over time. The study aims to compare the quality of life at 3 months between patients who received 3 months of personalised psychomotor therapy in addition to standard treatment and those who received standard treatment alone. The study lasted for 6 months, and the investigators expects a total of 128 people to participate in this research across several hospital establishments. This study evaluates the effectiveness of two types of treatment, divided into two randomly selected groups. To participate, individuals must have a medical diagnosis of major depressive disorder (MDD) and be between the ages of 20 and 60. They must have depressive symptoms with an HDRS score greater than 16 and provide informed consent. They must be treated or hospitalised at the Centre Hospitalier Esquirol or the Centre Hospitalier Henri Laborit (France). After providing consent, they will undergo an initial clinical interview that evaluates anxiety, self-esteem, pleasure, and quality of life. The therapist assessed the participant's muscle tone, gross motor skills, praxis, manual dexterity, rhythm, processing of sensory information, and body image. Following the assessment, the participant was randomly assigned to either the experimental or control group. The experimental group received the usual treatment for depression and underwent psychomotor therapy once a week for 12 weeks. The control group received the standard treatment for depression and underwent weekly telephone interviews. An assessment is scheduled at 1 month to evaluate the participant's health status, including any changes to treatment and assessment of anxiety and depressive symptoms. Another interim check-up is scheduled at 3 months to assess the patient's health status. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function. A final visit will be scheduled at 6 months for an assessment of the participant's health. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Personalised psychomotor therapy — The content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment. The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation. Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions. The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted. During each session, the participant will be required to complete the Duke health profile.
  • Other: Usual treatment — Participants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability.

Primary Outcomes

  • Difference in quality of life assessed using the Short-Form 36 Health Survey (at 3 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2026-08
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Esquirol
Collaborators: Direction Générale de l'Offre de Soins
Contact Information
Study Contact:
Aude PAQUET, Dr
+33555431127
aude.paquet@ch-esquirol-limoges.fr
Aude PAQUET
+33555431127
aude.paquet@ch-esquirol-limoges.fr
CH Esquirol
Interventions
  • Behavioral: Personalised psychomotor therapy — The content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment. The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation. Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions. The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted. During each session, the participant will be required to complete the Duke health profile.
  • Other: Usual treatment — Participants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability.
Study Locations (1 sites)
CH Esquirol, Limoges, 87000 France
Eligibility Criteria
Inclusion Criteria: * Diagnosis of depressive episode according to DSM-5 criteria. * HDRS \> 16 * Hospitalized or followed-up in one of the participating centers. * Affiliated or beneficiary of a social security scheme. * Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research). Exclusion Criteria: * Psychiatric comorbidity (non-tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders) * Sensory impairment or proven neurological pathology * History of neurological brain damage (including stroke, tumor, trauma resulting in loss of consciousness lasting more than 10 minutes) * Limited functional ability (difficulty in moving about, performing manual tasks or moving about) * Inability to understand questionnaires and study information * Inability to travel to the inclusion center (personal vehicle, public transport) * Pregnant or breast-feeding women, on declaration * Forced hospitalization, subjects under guardianship or trusteeship, lack of social protection
Conditions Breast Cancer, Triple Negative Breast Ca...
Phase PHASE1, PHASE2
Enrollment 31
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Stereotactic Radiation — Stereotactic Radiation to intact brain metastases or post-operative cavity.
  • Drug: Zimberelimab — One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.
  • Drug: Sacituzumab govitecan — SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.

Primary Outcomes

  • Phase I: Neurologic Toxicity (Up to 9 Weeks)
  • Phase II: Progression Free Survival (PFS) (Up to 12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-12-19
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 31 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Gilead Sciences
Principal Investigators:
  • Kamran Ahmed, MD (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
Contact Information
Study Contact:
Michelle DeJesus
813-745-6911
Michelle.DeJesus@moffitt.org
Kamran Ahmed, MD
kamran.ahmed@moffitt.org
Michelle DeJesus
813-745-6911
Michelle.DeJesus@moffitt.org
Moffitt Cancer Center
Interventions
  • Radiation: Stereotactic Radiation — Stereotactic Radiation to intact brain metastases or post-operative cavity.
  • Drug: Zimberelimab — One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.
  • Drug: Sacituzumab govitecan — SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.
Study Locations (1 sites)
Moffitt Cancer Center, Tampa, Florida 33612 United States
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated Informed Consent Form (ICF). * Stated willingness to comply with all study procedures and availability for the duration of the study. * Age ≥ 18. * Triple negative breast cancer; to fulfill the requirement of triple negative disease, a breast cancer must express (≤ 10%), by immunohistochemistry (IHC), of the hormone receptors (estrogen receptor \[ER\] and progesterone receptor \[PR\]). * Breast cancer as documented by extracranial tumor biopsy with brain metastases documented from MRI brain imaging or intracranial surgical pathology. * Eligible for Stereotactic radiosurgery (SRS) to brain metastases or to the post-operative bed. * Measurable brain disease per RANO-BM criteria1 that can be measured in at least one dimension as ≥ 0.5 cm for both intact brain metastases and post-operative cavities. * Maximum diameter of the largest intact brain metastases ≤ 4 cm. * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. * Symptomatic patients having undergone surgery or on stable doses of steroids ≤ 8 mg/day dexamethasone will be enrolled. * Prior treatment with taxane based chemotherapy with anthracyclines. * Individuals with prior SRS/fractioned stereotactic radiotherapy (FSRT) treatment will be allowed if active measurable disease has not previously been treated with radiation therapy. * Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the administration of each dose of study agent. * Male and female patients of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception. Exclusion Criteria: * Presence of leptomeningeal disease. * Women who are pregnant or breastfeeding. * Known history of HIV-1 or 2 with detectable viral load. * Active, known, or suspected autoimmune disease. Patients with an autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment are excluded. Exceptions are patients with type I diabetes mellitus, hypothyroidism only requiring thyroid replacement therapy, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Met any of the following criteria for cardiac disease: 1. Myocardial infarction or unstable angina pectoris within 6 months of enrollment 2. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation 3. New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of \< 40% * Any patient requiring supplemental oxygen therapy. * Have an active serious infection requiring antibiotics. * Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment. * Patients with prior history of non-breast cancer malignancies are excluded except in the case of adequately treated basal cell cancer, squamous cell skin cancer, chronic lymphocytic leukemia, or other cancers in remission not receiving active therapy for ≥ 2 years. * Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or that would interfere with the interpretation of safety results. * Major surgery or significant traumatic injury that has not been recovered from by 14 days before the initiation of study drug. * Have had a prior anticancer biologic agent within 4 weeks prior to enrollment or have had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to enrollment and have not recovered. * Have previously received topoisomerase 1 inhibitors in the setting of brain metastases. * Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of first dose of study drug. * Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded. * History of allergy or hypersensitivity to any of the study drugs or study drug components. * Prisoners or individuals who are involuntarily incarcerated. * Individuals who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
Conditions Breast Cancer
Phase NA
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test the effect of an affect-based exercise prescription on moderate-vigorous physical activity participation among survivors of breast cancer who completed primary treatment within the last 5 years. The main questions it aims to answer are: 1. Do at least 50% of participants assigned to the affect-based exercise prescription engage in ≥90 minutes of moderate-vigorous physical activity by the end of 12-weeks follow-up? 2. What level of satisfaction do breast cancer survivors who receive the affect-based exercise prescription report relative to breast cancer survivors who receive an effort-based exercise prescription. 3. What proportion of participants assigned to the affect-based exercise prescription stay enrolled in the study relative to the number of participants who stay enrolled in the effort-based exercise prescription. All participants will: * Be assigned to either the Affect-based exercise prescription or the Effort-based exercise prescription. * Participate in two meetings with a member of the study team meant to help them get started increasing weekly exercise. These meetings are the same for all participants. * Be asked to wear an activity monitor and respond to brief surveys for 10 straight days at 4 points in time: Baseline, 2weeks, 6weeks, and 12weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Core Exercise Promotion Program — Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
  • Behavioral: Affect-based exercise prescription — Participants assigned to Affect-Rx will receive instructions to "select a pace of exercise that makes you feel as good as possible." The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to "stay in the green zone" on the Feeling Scale.
  • Behavioral: Effort-based exercise prescription — Participants assigned to RPE-Rx will receive instructions to "select a pace that would make it challenging for you to carry on more than a short conversation." The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to "stay in the green zone" on the RPE Scale.

Primary Outcomes

  • Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 2 Weeks Follow-up (2-weeks follow-up assessment.)
  • Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 6 Weeks Follow-up (6-weeks follow-up assessment.)
  • Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 12 Weeks Follow-up (12-weeks follow-up assessment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-16
Completion: 2026-08-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dartmouth-Hitchcock Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Courtney J Stevens, PhD (PRINCIPAL_INVESTIGATOR) - Dartmouth-Hitcock Health
Contact Information
Study Contact:
Courtney J Stevens, PhD
6036509643
courtney.j.stevens@dartmouth.edu
Aislinn E Mitcham, BA
6036466545
aislinn.e.mitcham@hitchcock.org
Courtney J Stevens, PhD
603-646-5451
courtney.j.stevens@dartmouth.edu
Dartmouth-Hitchcock Clinic
Interventions
  • Behavioral: Core Exercise Promotion Program — Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
  • Behavioral: Affect-based exercise prescription — Participants assigned to Affect-Rx will receive instructions to "select a pace of exercise that makes you feel as good as possible." The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to "stay in the green zone" on the Feeling Scale.
  • Behavioral: Effort-based exercise prescription — Participants assigned to RPE-Rx will receive instructions to "select a pace that would make it challenging for you to carry on more than a short conversation." The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to "stay in the green zone" on the RPE Scale.
Study Locations (1 sites)
Dartmouth-Hitchcock Clinic, Lebanon, New Hampshire 03756 United States
Eligibility Criteria
Inclusion Criteria: * ≥18 years old * Within 5 years of completing primary cancer treatment (surgery, chemotherapy, and radiation) for Stage 0-III breast cancer * \<60 mins/week moderate-vigorous physical activity (MVPA) with no major changes for the past 6- months * Own an Android or iPhone smartphone (or tablet) and willing to use it to complete app-based surveys during assessment periods * Willing to wear the ActiGraph monitor during assessment periods * Access to internet to complete REDCap survey assessments Exclusion Criteria: * Non-English speaking/not able to read English * Evidence of major contraindications for exercise (informed by the 2020 Physical Activity Readiness-Questionnaire (PAR-Q)+) * Currently pregnant * History of severe mental illness or currently taking mood stabilizing medications (antipsychotics, anticonvulsants, or lithium) * Evidence of moderate-severe depressive symptoms (indicated by a score≥ 10 on the Patient Health Questionnaire-8) * Evidence of moderate-severe cognitive impairment (indicated by a score \< 3 on a 6-item cognitive screener) * Evidence of clinically significant substance use as indicated by a score of ≥ 2 on the CAGE- AID screener.
Conditions Chronic Kidney Diseases, Hyperkalemia, H...
Phase PHASE4
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this placebo-controlled, double-blinded cross-over trial is to test whether patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with chronic kidney disease stage 3b/4. The main questions it aims to answer are: * Does patiromer allow uptitration of irbesartan, resulting in a significant reduction in albuminuria and blood pressure? * Does patiromer allow uptitration of irbesartan, resulting in a significant reduction in blood pressure? The trial contains the following interventions: * Participants will be switched from their ACEi/ARB to a standardised dose of irbesartan (150 mg/d). * During two 12-week study periods, participants will receive either patiromer 8.4 g/d or placebo. The order of study periods is randomized. * At the start of each study period irbesartan will be up-titrated to 300 mg/d. * After 1 and 6 weeks, at both periods, plasma potassium will be measured and the irbesartan dose will be reduced to 150 mg/d in case plasma potassium exceeds 5.0 mmol/L. * At 12 weeks from the start of the study period, the endpoints will be assessed. * Between the two study periods, there is a 6-week washout. Irbesartan dose during the wash-out period will be 150mg/d. After washout, participants will switch from the patiromer arm to the placebo arm or vice versa.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Patiromer 8400 MG [Veltassa] — Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
  • Drug: Placebo — Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.

Primary Outcomes

  • Albumin-creatinine ratio (ACR) (At the end of both 12-week study periods (patiromer and placebo))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-04-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Center Groningen
Collaborators: Amsterdam University Medical Center, Frisius Medisch Centrum, Isala, Vifor Pharma, Inc., Dutch Kidney Foundation, Health Holland
Principal Investigators:
  • Liffert Vogt, prof. dr. (PRINCIPAL_INVESTIGATOR) - Amsterdam University Medical Centre
  • Aaltje Adema, dr. (PRINCIPAL_INVESTIGATOR) - Frisius Medisch Centrum
  • Femke Waanders, dr. (PRINCIPAL_INVESTIGATOR) - Isala Zwolle
Contact Information
Study Contact:
Martin de Borst, prof. dr.
+31503616161
m.h.de.borst@umcg.nl
Caspar van Lieshout, MD
+31503616161
c.j.van.lieshout@umcg.nl
Martin de Borst, prof. dr.
University Medical Center Groningen
Interventions
  • Drug: Patiromer 8400 MG [Veltassa] — Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
  • Drug: Placebo — Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
Study Locations (1 sites)
University Medical Center Groningen, Groningen, Netherlands
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * CKD stage 3b-4 (eGFR 15-44 mL/min/1.73 m2) * Albumin-creatinine ratio \>3 mg/mmol, or proteinuria \>0.05g/24u, or protein-creatinine ratio \> 5mg/mmol * Systolic blood pressure \>130 mmHg or use of one or more antihypertensive drugs; * Serum K+ 4.0-5.0 mmol/L; * On sub-maximal dose ACEi/ARB Exclusion Criteria: * prior ACEi/ARB dose reduction due to a drop in eGFR by \>25% in the last year; * history of severe hyperkalaemia (\>6.0 mmol/L) in the last year; * pregnancy or breastfeeding * life expectancy \<12 months * the use of lithium, potassium-sparing diuretics, potassium supplements, trimethoprim or NSAIDS * kidney transplant recipients, or diagnosis of autosomal dominant polycystic kidney disease or other non-glomerular kidney disease
Conditions Breast Cancer, Recurrent Breast Cancer, ...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of newly diagnosed or Recurrent Breast Carcinoma in frail or elderly patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Diffusing Alpha Radiation Emitters Therapy (DaRT) — An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms

Primary Outcomes

  • Feasibility -DaRT seed placement (immediately following the insertion procedure)
  • Safety- Adverse events (From Day 0)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-19
Completion: 2026-06
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alpha Tau Medical LTD.
Contact Information
Study Contact:
Liron Dimnik
+972542688602
LironD@alphatau.com
Aviya Hoida
+972547869466
aviyah@alphatau.com
Tanir Michal Eloise, MD
tanir@hadassah.org.il
Hadassah Medical Center
Interventions
  • Device: Diffusing Alpha Radiation Emitters Therapy (DaRT) — An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study Locations (1 sites)
Hadassah Medical Center, Jerusalem, 9777605 Israel
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed invasive breast tumor with no involvement of skin within 12 months. * Tumor size ≤ 4 centimeters in the longest diameter. * Tumor is not deemed as resectable with radical surgery or the patient does not wish to go through surgery * De-novo or recurrent lesions. * Single lesion per quadrant per subject. * Targeted lesion must be technically amenable for complete coverage (including margins) by the DaRT seeds. * Interstitial implant indication validated by multidisciplinary team. * ECOG Performance Status ≤3. * Life expectancy ≥12 months. * Women Age ≥65 or younger if unfit for standard of care. * Willing and have the ability to provide signed Informed Consent. * Blood tests values: * Leucocytes ≥3000mm3, * Absolute neutrophil count ≥1500mm3, * Platelets ≥100,000 mm3, * Total bilirubin ≤ 1.5xULN, * AST, SGOT, SGPT ≤2.5xULN, If Alkaline Phosphatase ≤ 4xULN, then transaminases are normal. * Creatinine ≤ 2.0xULN. * INR or Prothrombin time ≤1.5xULN Exclusion Criteria: * T4 category with skin involvement. * Ductal carcinoma in situ. * Inflammatory breast carcinoma. * Longest tumor diameter \>4 cm. * Patients with prior radiation to the same area within the past 6 months. * Has a known additional malignancy that is progressing or requires active treatment. * Patients undergoing immunosuppressive and/or systemic corticosteroid treatment except for steroid inhalations for treatment of asthma or lung disease * Subjects not willing to sign an informed consent.